Search

everythinglearnresearchcommunity

for

Search:↓

Polycystic Ovary Syndrome (PCOS) is a common condition in women that can cause metabolic, reproductive, and psychological issues, and requires lifestyle changes and medication for management.

Male hormones may play a role in the development of heart disease, and more research is needed to understand their effects.

Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.

The bulletin provides guidelines for diagnosing and managing PCOS, suggesting weight loss, hormonal contraceptives, and diabetes screening, with clomiphene for infertility and various treatments for excess hair.

Finasteride and minoxidil are effective for hair loss, but continued research is needed for better treatments.

Cells from balding scalps have more androgen receptors than cells from non-balding scalps.

Most women with excess hair growth have an underlying hormonal issue, often treated with medication and hair removal methods.

Hormone treatments for transgender individuals generally improve mental health and physical transition, with some health risks that require medical supervision.

Androgenetic alopecia in women needs more research and better management strategies.

Surgeons must understand the full care process for gender confirmation surgery to help transgender individuals effectively.

Hair ages due to genetics and environmental factors, leading to graying and thinning, with treatments available for some conditions.

Women with type 1 diabetes often have polycystic ovary syndrome and excess male hormones, which are frequently undiagnosed.

To manage diffuse hair loss, identify the cause, improve nutrition, remove triggers, and use specific treatments like minoxidil or finasteride.

PCOS is a common hormonal disorder in women, marked by symptoms like hair growth and menstrual issues, and requires personalized treatment.

Androgenetic alopecia involves genetics, hormones, and can be treated with medications or surgery.

Dermal Papilla cells are a promising tool for evaluating hair growth treatments.

Finasteride is a safe, effective treatment for hirsutism with fewer side effects.

The document concludes that early recognition and treatment of PCOS in adolescents is crucial for managing symptoms and long-term health risks.

Finasteride effectively reduces hair growth in women with idiopathic hirsutism, but requires careful contraception during treatment.

Estrogens and SERMs can help with skin aging, but their safety and effectiveness need more research.

Hirsutism is excessive hair growth in women often caused by polycystic ovarian syndrome, and identifying the cause is important for managing associated health risks.

Myo-inositol helps improve skin conditions and metabolic profiles in young women with PCOS.

Hair sensitivity to androgens is partly controlled by specific enzyme expressions in different hair areas.

PPAR agonists show promise for skin conditions but need more research before being a main treatment.

Insulin resistance contributes to hormone imbalances in many women with polycystic ovary syndrome.

The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.

Hormones and their receptors, especially androgens, play a key role in hair growth and disorders like baldness.

The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.

The document concludes with guidance for doctors on diagnosing and treating hirsutism effectively and safely.

The document concludes that understanding and treating hair loss requires recognizing its various types and using appropriate diagnostic tools and treatments.